Study S003274

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06481098
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 74
Start: 2024-05-28
Primary completion: 2025-05-02
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Obesity
Interventions: DRUG:HM15275; DRUG:Placebo of HM15275
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Part A: Safety and Tolerability [Up to Day 29]
Part B: Safety and Tolerability [Up to Day 57]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.